Key facts
- Medicovestor’s last known valuation is $53.0M (Dec 2025).
- It has raised $6.3M across 1 recorded rounds; the latest was Seed Round ($3.2M) in Nov 2025.
- Medicovestor has filed 1 Form D with the SEC, most recently Dec 2025 ($3.2M sold to 60 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Medicovestor
Funding rounds
1 roundsAbout Medicovestor
Developer of antibody-drug conjugate cancer therapy designed to merge antibodies' efficacy with the potency of small-molecule anticancer drugs. The company's precision medicines are meticulously crafted to target and eliminate cancer cells, prioritizing minimal harm to healthy cells and offering therapies for a diverse array of diseases, enabling the healthcare industry to provide effective approaches to cancer treatment and breakthrough precision medicines.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 7
- Website
- medicovestor.com/
- Ownership
- Privately Held (backing)
Medicovestor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medicovestor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medicovestor in its N-PORT filings yet. We sweep new filings monthly.